Cellectis is a clinical-stage French biotech developing allogeneic, or "off-the-shelf," CAR T-cell cancer immunotherapies. Unlike standard autologous CAR T therapies — which use a patient's own T-cells and take weeks to manufacture — Cellectis engineers T-cells from healthy donors in bulk, cryopreserves them, and ships them ready to use within days. The core technical challenge is preventing donor T-cells from attacking the patient (graft-versus-host disease), which Cellectis addresses using its proprietary TALEN gene-editing technology to knock out the T-cell receptor gene and other modifications. TALEN acts as molecular scissors to cut DNA at a precise location; Cellectis argues it offers greater precision and manufacturing efficiency than CRISPR-based alternatives used by competitors. Cellectis's most advanced wholly-owned program is lasme-cel, targeting CD22 in relapsed/refractory B-cell ALL, which entered pivotal Phase 2 in October 2025 and represents the primary near-term path to regulatory approval. A second wholly-owned program, eti-cel, targets both CD20 and CD22 in B-cell NHL — avoiding CD19, which most competing therapies target. Cellectis generates current revenue by licensing its gene-editing platform to partners including Allogene and AstraZeneca, earning upfront payments, milestones, and cost reimbursements. AstraZeneca holds roughly 44% of Cellectis on a fully diluted basis and fully reimburses Cellectis's R&D costs under their collaboration. Cellectis intends to commercialize lasme-cel and eti-cel directly upon approval.